Gene Therapy Market – Global Outlook & Forecast 2021-2031

Gene Therapy Market Introduction

Gene therapy is a medical field which focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material. Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein. In order to insert new genes directly into cells, a vehicle called a “vector” is used which is genetically engineered to deliver the gene.

Market - Headwinds & Tailwinds

The global gene therapy market is mainly driven by rising prevalence of various chronic diseases such as cancer & rare genetic disorders, robust pipeline, and growing government initiatives. Furthermore, increasing investment for R&D activities to launch more effective therapy is also playing a pivotal role in contributing to the market growth globally. However, high cost of therapy is likely to hinder the market growth to a certain extent.

Market Segmentation & Insights

The global gene therapy market has been analyzed from four main perspectives: Vector Type, Delivery Method, Disease Indication and Region.

Gene Therapy Market by Vector Type

Based on vector type, the gene therapy market has been segmented into viral vector and non-viral vector. The viral vector segment is further categorized into adenovirus, retrovirus, lentivirus, adeno-associated virus, herpes simplex virus and others (poxvirus, vaccinia virus, etc.). Whereas, non-viral vector is further categorized into naked DNA, transfection, liposomes, nanoparticles and others (nucleofection, transposons, etc.). The non-viral vector segment is expected to be fastest growing segment during the forecast period owing to its advantages over viral vector. Non-viral vectors are safer, cheaper, more reproducible and do not present DNA size limit.

Gene Therapy Market by Delivery Method

Based on delivery method, the gene therapy market has been segmented into in vivo gene therapy and ex vivo gene therapy. Ex vivo gene therapy refers to the process of genetically altering a person’s cells outside of the body and then transplanting them back in. Whereas, In vivo gene therapy refers to direct administration either intravenously, known as systemic administration, or locally to a specific organ of interest. The ex vivo gene therapy segment holds the largest share in the market. The growth of the segment can be attributed to its wide application in hematopoietic stem cells (HSCs), which are relevant to blood & immunological diseases and genetic diseases that affect tissues and organs easily accessible by blood cells.

Gene Therapy Market by Disease Indication

Based on disease indication, the gene therapy market has been segmented into cancer, neurological diseases, rare diseases, cardiovascular diseases and others (infectious diseases, hepatological diseases, etc.). The cancer segment accounted for the largest share in the market. The growth of the segment can be attributed to the rising prevalence of different types of cancer all over the world coupled with the approval of different types of gene therapy for the treatment of cancer. Furthermore, presence of large number of gene therapy candidates in pipeline is also expected to boost the growth of the market in the forecast period.

Gene Therapy Market by Region

Based on region, the global gene therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the gene therapy market, followed by Asia Pacific. The large share of North America in the global market can largely be attributed to the advanced healthcare infrastructure, presence of prominent players, rising prevalence of cancer in the region, rising investments in the R&D of gene therapy and robust therapy pipeline.

 Competitive Landscape

The gene therapy market is marked by presence of prominent players such Novartis AG, Amgen Inc., Gilead Sciences, Inc., Bayer AG, REGENXBIO Inc., uniQure N.V., Voyager Therapeutics, Spark Therapeutics, Inc., SIBIONO, and Orchard Therapeutics plc. Other players operating in the market are bluebird bio, Inc., Audentes Therapeutics, Ionis Pharmaceuticals, Sarepta Therapeutics, among others.

Snapshot: Industry Developments

• In Mar 2021, SIRION Biotech signed a gene therapy collaboration with Sanofi to work with Heidelberg University Hospital’s Professor Dirk Grimm in Germany to develop next-generation tissue-selective adeno-associated virus (AAV) vectors for gene therapies
• In Jan 2021, MeiraGTx announced that FDA granted fast track designation to its AAV-CNGA3, a gene therapy candidate for the treatment of achromatopsia
• In Dec 2020, Neurogene Inc., announced that the European Medicines Agency (EMA) granted Orphan Drug Designation (ODD) to its adeno-associated virus vector (AAV) with engineered transgene encoding the human AGA gene for patients diagnosed with aspartylglucosaminuria
• In Dec 2020, Janssen Pharmaceuticals, announced that it has acquired US-based biotechnology company Hemera Biosciences’ investigational gene therapy, HMR59, for the preservation of vision in patients with geographic atrophy, a form of age-related macular degeneration (AMD)

Key Insights Captured in the Report

• Quantitative (market size and forecasts) and qualitative insights of the market across years - historical years, current year and forecasted years
• Deep-rooted insights on headwinds, tailwinds and opportunities prevailing in the market
• Quantitative (market size and forecasts) and qualitative insights at segment and sub-segment level
• Comprehensive quantitative (market size and forecasts) and qualitative insights on geographic, regional and country level markets
• Granular insights on the competitive landscape prevailing in the market
• Competitive mapping of strategic developments 

Scope of the Gene Therapy Market Report: